Abstract
Because the results with cobalt-57-bleomycin (57Co-bleo) as a tumour-seeking agent in patients with pulmonary tumours were promising, a prospective study was carried out to test the sensitivity and selectivity of this technique for metastases in lung hila and mediastinum in a group of patients with bronchial cancer. The sensitivity of 57Co-bleo scintigraphy appeared to be higher than that of routine radiological investigations and mediastinoscopy. For this reason it is suggested that 57Co-bleo scintigraphy can be used as a method to select patients for mediastinoscopy.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Grove R. B., Reba R. C., Eckelman W. C., Goodyear M. Clinical evaluation of radiolabeled bleomycin (BLEO) for tumor detection. J Nucl Med. 1974 Jun;15(6):386–390. [PubMed] [Google Scholar]
- Peset R., Gimeno F., van Haeringen J. R., Beekhuis H., Woldring M. G. Comparison of 133Xenon regional studies during spontaneous breathing and bronchospirometry. Scand J Respir Dis. 1974;55(2):91–98. [PubMed] [Google Scholar]
- Rasker J. J., Poll A. M., Beekhuis H., Woldring M. G., Nieweg H. O. Some experience with 57Co-labeled bleomycin as a tumor-seeking agent. J Nucl Med. 1975 Nov;16(11):1058–1069. [PubMed] [Google Scholar]
- van de Poll M. A., Versluis A., Rasker J. J., Jurjens H., Woldring M. G. Labelling of bleomycin with cobalt-57, indium-111, technetium-99m, mercury-197, lead-203, and copper-67. Nuklearmedizin. 1976 Apr;15(2):86–90. [PubMed] [Google Scholar]